Patents Assigned to Diagnostics Hybrids, Inc.
-
Patent number: 10564159Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays. Such improvements are based upon the superior performance of assays comprising a chimeric TSH receptor in the presence of a glucocorticoid including, but not limited to, dexamethasone.Type: GrantFiled: September 26, 2017Date of Patent: February 18, 2020Assignee: Diagnostic Hybrids, Inc.Inventors: Leonard Kohn, James L. Brown, David R. Scholl, Yunsheng Li, Giorgio Napolitano
-
Patent number: 10088481Abstract: The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus. Sapogenin is used as a detergent to permeabilize the cells for entry of the monoclonal antibodies to react with intracellular antigens. The cells are stained with fluorescently labeled monoclonal antibodies against the viral antigens along with a background stain and a fluorescent nuclear stain. This counter staining decreases background and allows co-localization of antigen and nuclear structures for enhanced detection.Type: GrantFiled: January 21, 2015Date of Patent: October 2, 2018Assignee: Diagnostic Hybrids, Inc.Inventors: David R. Scholl, James L. Brown, Joseph A. Jollick, Jr., Ronald Lollar
-
Patent number: 10041943Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.Type: GrantFiled: August 21, 2017Date of Patent: August 7, 2018Assignee: Diagnostic Hybrids, Inc.Inventor: James L Brown
-
Patent number: 9797901Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays. Such improvements are based upon the superior performance of assays comprising a chimeric TSH receptor in the presence of a glucocorticoid including, but not limited to, dexamethasone.Type: GrantFiled: October 14, 2013Date of Patent: October 24, 2017Assignee: Diagnostics Hybrid, Inc.Inventors: Leonard Kohn, Jim Brown, David Scholl, Yunsheng Li, Giorgio Napolitano
-
Patent number: 9739775Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.Type: GrantFiled: December 1, 2014Date of Patent: August 22, 2017Assignee: Diagnostic Hybrids, Inc.Inventor: James L. Brown
-
Patent number: 9689018Abstract: The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.Type: GrantFiled: August 4, 2014Date of Patent: June 27, 2017Assignees: Diagnostic Hybrids, Inc., University Hospitals Cleveland Medical CenterInventors: David R. Scholl, Yung T. Huang, Patricia Gail Ray Goodrum
-
Patent number: 9535066Abstract: The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples.Type: GrantFiled: August 31, 2015Date of Patent: January 3, 2017Assignee: Diagnostic Hybrids, Inc.Inventors: Giuseppe Gerna, Antonella Sarasini, Maria Grazia Revello
-
Patent number: 9157915Abstract: The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples.Type: GrantFiled: July 18, 2013Date of Patent: October 13, 2015Assignee: DIAGNOSTIC HYBRIDS, INC.Inventors: Giuseppe Gerna, Antonella Sarasini, Maria Grazia Revello
-
Patent number: 8975016Abstract: The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus. Sapogenin is used as a detergent to permeabilize the cells for entry of the monoclonal antibodies to react with intracellular antigens. The cells are stained with fluorescently labeled monoclonal antibodies against the viral antigens along with a background stain and a fluorescent nuclear stain. This counter staining decreases background and allows co-localization of antigen and nuclear structures for enhanced detection.Type: GrantFiled: June 22, 2011Date of Patent: March 10, 2015Assignee: Diagnostic Hybrids, Inc.Inventors: David R. Scholl, James L. Brown, Joseph A. Jollick, Jr., Ronald Lollar
-
Publication number: 20150031016Abstract: The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.Type: ApplicationFiled: August 4, 2014Publication date: January 29, 2015Applicant: Diagnostic Hybrids Inc.Inventors: David R. Scholl, Yung T Huang, Patricia Gail Ray Goodrum
-
Patent number: 8926981Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.Type: GrantFiled: September 12, 2012Date of Patent: January 6, 2015Assignee: Diagnostic Hybrids, Inc.Inventor: James L. Brown
-
Patent number: 8828673Abstract: The present invention generally relates to the field of diagnostic microbiology, and, more particularly; to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.Type: GrantFiled: March 1, 2012Date of Patent: September 9, 2014Assignees: Diagnostic Hybrids Inc, University Hospitals of ClevelandInventors: David R. Scholl, Yung T. Huang, Patricia Gail Ray Goodrum
-
Patent number: 8563257Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays. Such improvements are based upon the superior performance of assays comprising a chimeric TSH receptor in the presence of a glucocorticoid including, but not limited to, dexamethasone.Type: GrantFiled: June 12, 2009Date of Patent: October 22, 2013Assignee: Diagnostic Hybrids, Inc.Inventors: Leonard Kohn, Jim Brown, David Scholl, Yunsheng Li, Giorgio Napolitano
-
Patent number: 8492097Abstract: The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples.Type: GrantFiled: April 24, 2006Date of Patent: July 23, 2013Assignee: Diagnostic Hybrids, Inc.Inventors: Giuseppe Gerna, Antonella Sarasini, Maria Grazia Revello
-
Patent number: 8293879Abstract: The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.Type: GrantFiled: October 1, 2007Date of Patent: October 23, 2012Assignee: Diagnostic Hybrids, Inc.Inventor: James L. Brown
-
Patent number: 8003314Abstract: The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus. Sapogenin is used as a detergent to permeabilize the cells for entry of the monoclonal antibodies to react with intracellular antigens. The cells are stained with fluorescently labeled monoclonal antibodies against the viral antigens along with a background stain and a fluorescent nuclear stain. This counter staining decreases background and allows co-localization of antigen and nuclear structures for enhanced detection.Type: GrantFiled: April 16, 2009Date of Patent: August 23, 2011Assignee: Diagnostic Hybrids, Inc.Inventors: David R. Scholl, James L. Brown, Joseph A. Jollick, Jr., Ronald Lollar
-
Patent number: 7846655Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.Type: GrantFiled: November 3, 2004Date of Patent: December 7, 2010Assignee: Diagnostic Hybrids, Inc.Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
-
Publication number: 20100233674Abstract: The invention provides cell lines that are useful for the rapid detection and production of influenza and parainfluenza viruses. In particular, the invention relates to transgenic cells with increased sensitivity to infection by influenza A, influenza B, or parainfluenza 3 viruses, or which are capable of enhanced productivity of infectious virions. The invention is suitable for use in culturing clinical influenza and parainfluenza virus isolates and for the production of influenza and parainfluenza virus for vaccine formulations, as antigen preparations for diagnostic applications, and for screening antiviral drugs.Type: ApplicationFiled: December 19, 2006Publication date: September 16, 2010Applicants: University Hospitals of Cleveland, Diagnostic Hybrids, Inc.Inventors: Yung T. Huang, Yunsheng Li
-
Publication number: 20100173280Abstract: The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.Type: ApplicationFiled: September 19, 2006Publication date: July 8, 2010Applicant: Diagnostic Hybrids, IncInventors: Yung T. Huang, Joseph A. Jollick, JR.
-
Patent number: 7442508Abstract: The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.Type: GrantFiled: April 28, 2006Date of Patent: October 28, 2008Assignee: Diagnostic Hybrids, Inc.Inventors: David R. Scholl, Yung T. Huang, Patricia Gail Ray Goodrum